Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.68 |
| ▸ | DRD3 | P35462 | 3/20 | 0.68 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.68 |
| ▸ | HTR3B | O95264 | 1/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | HTR3A | P46098 | 1/20 | 0.68 |
| ▸ | HTR6 | P50406 | 1/20 | 0.68 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.68 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8189587 | 0.85 | ALDH1A1 (0.63) | DRD2DRD3HTR3EHTR3BADRB1 | |
| SCHEMBL3704117 | 0.82 | KDM4E (0.63) | DRD2DRD3ALDH1A1KDM4EHTR1A | |
| SCHEMBL6635193 | 0.82 | KDM4E (0.62) | DRD2DRD3MAPTALDH1A1KDM4E | |
| SCHEMBL29396943 | 0.81 | HTR3A (1.00) | DRD2DRD3HTR3EHTR3BADRB1 | |
| SCHEMBL6366499 | 0.81 | HTR3A (1.00) | DRD2DRD3HTR3EHTR3BADRB1 | |
| SCHEMBL379 | 0.81 | HTR3A (1.00) | DRD2DRD3HTR3EHTR3BADRB1 | |
| SCHEMBL26418370 | 0.81 | DRD2 (0.71) | DRD2DRD3HTR3EHTR3BADRB1 | |
| SCHEMBL14529139 | 0.81 | ALDH1A1 (0.64) | DRD2DRD3HTR3EHTR3BADRB1 | |
| SCHEMBL3710253 | 0.81 | ADRB1 (0.65) | ADRB1HTR3AHTR1A | |
| SCHEMBL8764013 | 0.81 | KDM4E (0.84) | DRD2DRD3ALDH1A1KDM4EHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1888559-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | Wyeth a Corporation of the State of Delaware (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| WO-2006135839-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | WYETH (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | HTR5A, HTR2C, HTR1D | DRD2 22/4885DRD3 36/4885HTR3E 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.